The French manufacturer of natural active ingredients for the cosmetics, nutraceutical, pharmaceutical industries is strengthening its position in the nutrition market with the acquisition of a majority stake in BioActor, a leader in the development and commercialisation natural active ingredients used by leading food supplement brands.
Founded in 2011 and located on the Maastricht Health Campus, Netherlands, BioActor develops and markets clinically evaluated polyphenols extracted from edible plants and fruits and used by leading food supplement brands worldwide.
“Thanks to an in-house clinical research team with direct access to a state-of-the-art clinical research facility and a genuine passion for innovation, BioActor’s health ingredients are all first-in-class, offering supplement brands the opportunity to develop unique solutions to consumers worldwide,” said Solabia in a statement.
BioActor currently exports to more than 20 countries worldwide.
Hans van der Saag, BioActor’s founder, retains a minority share and his role as CEO of the company.
Solabia is already present in the nutrition segment through original ingredients recognized for their health benefits, including Algatech’s microalgae-derived active ingredients. This strategic investment will allow Solabia to benefit from a wider range of ingredients and from BioActor’s expertise, strengthening its nutrition division positioning on this fast-growing market, as brands increasingly look for high quality active ingredients that combine naturality with proof of efficacy.
BioActor will become a centre of excellence for innovation and clinical research within Solabia’s nutrition division.
